Qualigen Therapeutics, Inc. Provides Update on Product Development Priorities and Reports Second Quarter and Six Month 2021 Financial Results
August 17, 2021 08:00 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif.,, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announces its intention to prioritize its focus to its oncology pipeline that includes QN-247...
Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19
July 14, 2021 07:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral...
Qualigen Therapeutics Announces Inclusion in Russell Microcap® Index
June 08, 2021 07:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral...
Qualigen Therapeutics, Inc. to Present at the LD Micro Invitational XI Conference
June 02, 2021 07:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral...
Qualigen Therapeutics, Inc. Appoints Tariq Arshad, MD, MBA as Chief Medical Officer
May 19, 2021 07:30 ET
|
Qualigen Therapeutics, Inc.
New Position Created to Deepen Clinical Expertise and Advance Pipeline Therapeutic Programs CARLSBAD, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a...
Qualigen Therapeutics, Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 14, 2021 13:35 ET
|
Qualigen Therapeutics, Inc.
Conference call scheduled for May 18, 2021 at 4:10 p.m. EDT. Revenues Increased 30 Percent to $1.9 Million Compared to $1.5 Million in the Same Quarter of the Previous YearOn Track to File an IND...
Qualigen Therapeutics, Inc. to present at the Benzinga Biotech Small Cap Conference
March 18, 2021 08:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...
Qualigen Therapeutics, Inc. Promotes Shishir Sinha to Chief Operating Officer Position
March 09, 2021 08:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...
Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference
March 08, 2021 08:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...
Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL
March 01, 2021 08:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...